In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study

Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, David B., Hawser, Stephen, Gemmell, Curtis G., Sahm, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748095/
https://www.ncbi.nlm.nih.gov/pubmed/29527229
http://dx.doi.org/10.1155/2017/3948626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748095/
https://www.ncbi.nlm.nih.gov/pubmed/29527229
http://dx.doi.org/10.1155/2017/3948626

Ejemplares similares